Kite Pharma

Expanding CAR T treatment centers globally is about more than numbers—it’s about breaking down barriers so that even more patients can access these potentially curative treatments. Our team is working hard to grow our network, which includes bringing cell therapies to large integrated community practices and beyond.

Our team is gearing up to attend this year’s Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. We believe cell therapy has the ability to change the way cancer is treated and look forward to meeting with peers who share our commitment to furthering the curative potential of these innovative treatments. #Tandem25

We’re here at The EBMT- European Hematology Association (EHA) 7th European CAR T-cell Meeting 2025 to discuss the curative potential of cell therapy for people living with certain types of blood cancers. Our team is proud to be at the forefront of the latest clinical advances in CAR T-cell therapy, and we’re committed to changing the treatment landscape for patients living with blood cancers. #CART25

Cancer is more than a diagnosis. It’s a story of challenges, milestones and triumphs. This #WorldCancerDay, we reaffirm our commitment to help change the way cancer is treated by seeing the person behind the diagnosis. As the global leader in cell therapy, we remain relentless in our pursuit of a cure. Together with oncologists, advocates and Gilead Sciences, we strive to improve patient lives and global health for generations to come. #UnitedByUnique

We believe our people are our greatest asset, and we’re launching a new series to spotlight some of them. In honor of #BlackHistoryMonth, we’re highlighting Tashica Williams Amirgholizadeh, whose unique journey to patent law led to her making a meaningful impact at Gilead. #GileadLife 

The Kite team welcomed U.S. Rep. April McClain Delaney to our CAR T-cell therapy manufacturing facility in Maryland this week. We had the opportunity to discuss the curative potential of our treatments and the importance of research so innovation can move forward.    Thank you, Rep. McClain Delaney, for your time and support—we're excited to continue pushing the boundaries of what’s possible in cell therapy. 

At Kite, we believe in the transformative power of #celltherapy. By combining leading-edge research, global in-house manufacturing and a singular focus on cell therapy—we’re helping to advance cancer treatment to offer new possibilities for patients in need of breakthrough options.  

As we advance the technology to bring CAR T-cell therapy into earlier lines of treatment and expand its application to new disease areas, we must also enhance patient access to this transformative treatment that has changed the standard of care. We’re at a tipping point to unlock broad CAR T access, and we must evolve the infrastructure to propel CAR T into the status quo. My recent STAT article focuses on how we can bring the curative potential of CAR T-cell therapy to more eligible patients: https://lnkd.in/g2_PiB9A    #celltherapy #innovation #patients

CAR T-cell therapy is changing the way cancer is treated and providing many patients with certain types of blood cancer with the potential for cure. To date, Kite cell therapies have been used to treat more than 25,000 patients worldwide.

Happy Holidays from the Kite team. We’re grateful for everyone who has helped advance our mission of achieving cures with cell therapy this year.